This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fung-Tomc, J. C.
Right arrow Articles by Bonner, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fung-Tomc, J. C.
Right arrow Articles by Bonner, D. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2000, p. 3351-3356, Vol. 44, No. 12
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Antibacterial Spectrum of a Novel Des-Fluoro(6) Quinolone, BMS-284756

Joan C. Fung-Tomc,* Beatrice Minassian, Benjamin Kolek, Elizabeth Huczko, Lauren Aleksunes, Terry Stickle, Thomas Washo, Elizabeth Gradelski, Lourdes Valera, and Daniel P. Bonner

Department of Microbiology, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492

Received 23 June 2000/Returned for modification 3 August 2000/Accepted 21 September 2000

The in vitro spectrum of a novel des-fluoro(6) quinolone, BMS-284756, was compared with those of five fluoroquinolones (trovafloxacin, moxifloxacin, levofloxacin, ofloxacin, and ciprofloxacin). BMS-284756 was among the most active and often was the most active quinolone against staphylococci (including methicillin-resistant strains), streptococci, pneumococci (including ciprofloxacin-nonsusceptible and penicillin-resistant strains), and Enterococcus faecalis. BMS-284756 inhibited approx 60 to approx 70% of the Enterococcus faecium (including vancomycin-resistant) strains and 90 to 100% of the Enterobacteriaceae strains and gastroenteric bacillary pathogens at the anticipated MIC susceptible breakpoint (<= 4 µg/ml). Against the nonfermenters, BMS-284756 inhibited 90 to 100% of Pseudomonas fluorescens, Pseudomonas stutzeri, Stenotrophomonas maltophilia, Flavobacterium spp., and Acinetobacter spp. and 72% of Pseudomonas aeruginosa strains at 4 µg/ml. Against anaerobic bacteria, BMS-284756 was among the most active, inhibiting essentially all strains tested. It had very low MICs against the fastidious and atypical microbial species, in particular against mycoplasmas or ureaplasmas, Borrelia burgdorferi, chlamydia, and gonococci. These results indicate that with its broad antibacterial spectrum, BMS-284756 should be evaluated clinically for the treatment of community and nosocomial infections.

* Corresponding author. Mailing address: Bristol-Myers Squibb Company, Department of Microbiology-104, 5 Research Pkwy., Wallingford, CT 06492. Phone: (203) 677-6370. Fax: (203) 677-6771. E-mail: fungtomj{at}bms.com.

Antimicrobial Agents and Chemotherapy, December 2000, p. 3351-3356, Vol. 44, No. 12
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Murakami, K., Okimoto, T., Kodama, M., Tanahashi, J., Fujioka, T., Ikeda, F., Muraoka, H., Takigawa, M., Saika, T., Hasegawa, M., Kobayashi, I. (2009). Sitafloxacin Activity against Helicobacter pylori Isolates, Including Those with gyrA Mutations. Antimicrob. Agents Chemother. 53: 3097-3099 [Abstract] [Full Text]  
  • Krishna, G., Kisicki, J. C., Olsen, S., Grasela, D. M., Wang, Z. (2007). The Effect of Omeprazole on the Bioavailability and Safety of Garenoxacin in Healthy Volunteers. J Clin Pharmacol 47: 628-632 [Abstract] [Full Text]  
  • Lalucat, J., Bennasar, A., Bosch, R., Garcia-Valdes, E., Palleroni, N. J. (2006). Biology of Pseudomonas stutzeri. Microbiol. Mol. Biol. Rev. 70: 510-547 [Abstract] [Full Text]  
  • Anguita-Alonso, P., Rouse, M. S., Piper, K. E., Steckelberg, J. M., Patel, R. (2006). Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci.. Antimicrob. Agents Chemother. 50: 1263-1267 [Abstract] [Full Text]  
  • Galbraith, K. M., Ng, A. C., Eggers, B. J., Kuchel, C. R., Eggers, C. H., Samuels, D. S. (2005). parC Mutations in Fluoroquinolone-Resistant Borrelia burgdorferi. Antimicrob. Agents Chemother. 49: 4354-4357 [Abstract] [Full Text]  
  • Alyaseen, S. A., Piper, K. E., Rouse, M. S., Steckelberg, J. M., Patel, R. (2005). Selection of Cross-Resistance following Exposure of Pseudomonas aeruginosa Clinical Isolates to Ciprofloxacin or Cefepime. Antimicrob. Agents Chemother. 49: 2543-2545 [Abstract] [Full Text]  
  • Van Wart, S., Phillips, L., Ludwig, E. A., Russo, R., Gajjar, D. A., Bello, A., Ambrose, P. G., Costanzo, C., Grasela, T. H., Echols, R., Grasela, D. M. (2004). Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections. Antimicrob. Agents Chemother. 48: 4766-4777 [Abstract] [Full Text]  
  • Pereyre, S., Renaudin, H., Bebear, C., Bebear, C. M. (2004). In Vitro Activities of the Newer Quinolones Garenoxacin, Gatifloxacin, and Gemifloxacin against Human Mycoplasmas. Antimicrob. Agents Chemother. 48: 3165-3168 [Abstract] [Full Text]  
  • Yoo, B. K, Triller, D. M, Yong, C.-S., Lodise, T. P (2004). Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections. The Annals of Pharmacotherapy 38: 1226-1235 [Abstract] [Full Text]  
  • Christiansen, K. J., Bell, J. M., Turnidge, J. D., Jones, R. N. (2004). Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001. Antimicrob. Agents Chemother. 48: 2049-2055 [Abstract] [Full Text]  
  • Smith, R. P., Baltch, A. L., Ritz, W. J., Carpenter, A. N., Halse, T. A., Bopp, L. H. (2004). In Vitro Activities of Garenoxacin and Levofloxacin against Chlamydia pneumoniae Are Not Affected by Presence of Mycoplasma DNA. Antimicrob. Agents Chemother. 48: 2081-2084 [Abstract] [Full Text]  
  • Jones, R. N., Gordon, K. A., Biedenbach, D. J. (2004). Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: report from the garenoxacin international bridging study. J Antimicrob Chemother 53: 258-265 [Abstract] [Full Text]  
  • Entenza, J. M., Vouillamoz, J., Glauser, M. P., Moreillon, P. (2004). Efficacy of Garenoxacin in Treatment of Experimental Endocarditis Due to Staphylococcus aureus or Viridans Group Streptococci. Antimicrob. Agents Chemother. 48: 86-92 [Abstract] [Full Text]  
  • Andes, D., Craig, W. A. (2003). Pharmacodynamics of the New Des-F(6)-Quinolone Garenoxacin in a Murine Thigh Infection Model. Antimicrob. Agents Chemother. 47: 3935-3941 [Abstract] [Full Text]  
  • Perez-Vazquez, M., Roman, F., Aracil, B., Canton, R., Campos, J. (2003). In Vitro Activities of Garenoxacin (BMS-284756) against Haemophilus influenzae Isolates with Different Fluoroquinolone Susceptibilities. Antimicrob. Agents Chemother. 47: 3539-3541 [Abstract] [Full Text]  
  • Grohs, P., Houssaye, S., Aubert, A., Gutmann, L., Varon, E. (2003). In Vitro Activities of Garenoxacin (BMS-284756) against Streptococcus pneumoniae, Viridans Group Streptococci, and Enterococcus faecalis Compared to Those of Six Other Quinolones. Antimicrob. Agents Chemother. 47: 3542-3547 [Abstract] [Full Text]  
  • Liebetrau, A., Rodloff, A. C., Behra-Miellet, J., Dubreuil, L. (2003). In Vitro Activities of a New Des-Fluoro(6) Quinolone, Garenoxacin, against Clinical Anaerobic Bacteria. Antimicrob. Agents Chemother. 47: 3667-3671 [Abstract] [Full Text]  
  • Hayakawa, H., Fukushima, Y., Kato, H., Fukumoto, H., Kadota, T., Yamamoto, H., Kuroiwa, H., Nishigaki, J., Tsuji, A. (2003). METABOLISM AND DISPOSITION OF NOVEL DES-FLUORO QUINOLONE GARENOXACIN IN EXPERIMENTAL ANIMALS AND AN INTERSPECIES SCALING OF PHARMACOKINETIC PARAMETERS. Drug Metab. Dispos. 31: 1409-1418 [Abstract] [Full Text]  
  • Ricci, V., Piddock, L. (2003). Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones. J Antimicrob Chemother 52: 605-609 [Abstract] [Full Text]  
  • Morosini, M.-I., Loza, E., del Campo, R., Almaraz, F., Baquero, F., Canton, R. (2003). Fluoroquinolone-Resistant Streptococcus pneumoniae in Spain: Activities of Garenoxacin against Clinical Isolates Including Strains with Altered Topoisomerases. Antimicrob. Agents Chemother. 47: 2692-2695 [Abstract] [Full Text]  
  • Gordon, K. A., Rhomberg, P. R., Jones, R. N. (2003). Commercial Broth Microdilution Panel Validation and Reproducibility Trials for Garenoxacin (BMS-284756), a Novel Desfluoroquinolone. J. Clin. Microbiol. 41: 3967-3969 [Abstract] [Full Text]  
  • Gajjar, D. A., Bello, A., Ge, Z., Christopher, L., Grasela, D. M. (2003). Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects. Antimicrob. Agents Chemother. 47: 2256-2263 [Abstract] [Full Text]  
  • Ameyama, S., Shinmura, Y., Takahata, M. (2003). Inhibitory Activities of Quinolones against DNA Gyrase of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 47: 2327-2329 [Abstract] [Full Text]  
  • Credito, K. L., Jacobs, M. R., Appelbaum, P. C. (2003). Time-Kill Studies of the Antianaerobe Activity of Garenoxacin Compared with Those of Nine Other Agents. Antimicrob. Agents Chemother. 47: 1399-1402 [Abstract] [Full Text]  
  • Hecht, D. W., Osmolski, J. R. (2003). Activities of Garenoxacin (BMS-284756) and Other Agents against Anaerobic Clinical Isolates. Antimicrob. Agents Chemother. 47: 910-916 [Abstract] [Full Text]  
  • Pankuch, G. A., Jacobs, M. R., Appelbaum, P. C. (2003). Postantibiotic Effects of Garenoxacin (BMS-284756) against 12 Gram-Positive or -Negative Organisms. Antimicrob. Agents Chemother. 47: 1140-1142 [Abstract] [Full Text]  
  • Andrews, J., Honeybourne, D., Jevons, G., Boyce, M., Wise, R., Bello, A., Gajjar, D. (2003). Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects. J Antimicrob Chemother 51: 727-730 [Abstract] [Full Text]  
  • Waites, K. B., Crabb, D. M., Bing, X., Duffy, L. B. (2003). In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 47: 161-165 [Abstract] [Full Text]  
  • Rodriguez-Cerrato, V., McCoig, C. C., Saavedra, J., Barton, T., Michelow, I. C., Hardy, R. D., Bowlware, K., Iglehart, J., Katz, K., McCracken, G. H. Jr (2003). Garenoxacin (BMS-284756) and Moxifloxacin in Experimental Meningitis Caused by Vancomycin-Tolerant Pneumococci. Antimicrob. Agents Chemother. 47: 211-215 [Abstract] [Full Text]  
  • Lister, P. D. (2003). Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones. J Antimicrob Chemother 51: 199-202 [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T. (2002). In Vitro Activities of Garenoxacin (BMS 284756) against 108 Clinical Isolates of Gardnerella vaginalis. Antimicrob. Agents Chemother. 46: 3995-3996 [Abstract] [Full Text]  
  • Ince, D., Zhang, X., Silver, L. C., Hooper, D. C. (2002). Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Garenoxacin (BMS-284756, T-3811ME), a New Desfluoroquinolone. Antimicrob. Agents Chemother. 46: 3370-3380 [Abstract] [Full Text]  
  • Snydman, D. R., Jacobus, N. V., McDermott, L. A., Ruthazer, R., Goldstein, E., Finegold, S., Harrell, L., Hecht, D. W., Jenkins, S., Pierson, C., Venezia, R., Rihs, J., Gorbach, S. L. (2002). In Vitro Activities of Newer Quinolones against Bacteroides Group Organisms. Antimicrob. Agents Chemother. 46: 3276-3279 [Abstract] [Full Text]  
  • Donati, M., Pollini, G. M., Sparacino, M., Fortugno, M. T., Laghi, E., Cevenini, R. (2002). Comparative in vitro activity of garenoxacin against Chlamydia spp.. J Antimicrob Chemother 50: 407-410 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T. (2002). In Vitro Activities of Garenoxacin (BMS-284756) against 170 Clinical Isolates of Nine Pasteurella Species. Antimicrob. Agents Chemother. 46: 3068-3070 [Abstract] [Full Text]  
  • Jones, M. E., Critchley, I. A., Karlowsky, J. A., Blosser-Middleton, R. S., Schmitz, F.-J., Thornsberry, C., Sahm, D. F. (2002). In Vitro Activities of Novel Nonfluorinated Quinolones PGE 9262932 and PGE 9509924 against Clinical Isolates of Staphylococcus aureus and Streptococcus pneumoniae with Defined Mutations in DNA Gyrase and Topoisomerase IV. Antimicrob. Agents Chemother. 46: 1651-1657 [Abstract] [Full Text]  
  • Gordon, K. A., Pfaller, M. A., Jones, R. N., the SENTRY Participants Group, (2002). BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10 000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000). J Antimicrob Chemother 49: 851-855 [Abstract] [Full Text]  
  • Schmitz, F.-J., Milatovic, D., Boos, M., Mayer, S., Fluit, A. C. (2002). In vitro activity of the novel des-F(6) quinolone BMS-284756 against genetically characterized clinical streptococcal isolates, including isolates with reduced quinolone susceptibility. J Antimicrob Chemother 49: 698-701 [Full Text]  
  • Low, D. E., Muller, M., Duncan, C. L., Willey, B. M., de Azavedo, J. C., McGeer, A., Kreiswirth, B. N., Pong-Porter, S., Bast, D. J. (2002). Activity of BMS-284756, a Novel Des-Fluoro(6) Quinolone, against Staphylococcus aureus, Including Contributions of Mutations to Quinolone Resistance. Antimicrob. Agents Chemother. 46: 1119-1121 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. (2002). In Vitro Activities of the Des-Fluoro(6) Quinolone BMS-284756 against Aerobic and Anaerobic Pathogens Isolated from Skin and Soft Tissue Animal and Human Bite Wound Infections. Antimicrob. Agents Chemother. 46: 866-870 [Abstract] [Full Text]  
  • Schmitz, F.-J., Boos, M., Mayer, S., Kohrer, K., Scheuring, S., C. Fluit, A. (2002). In Vitro Activities of Novel Des-Fluoro(6) Quinolone BMS-284756 against Mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus Selected with Different Quinolones. Antimicrob. Agents Chemother. 46: 934-935 [Full Text]  
  • Schmitz, F.-J., Boos, M., Mayer, S., Jagusch, H., Fluit, A. C. (2002). Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 49: 283-287 [Abstract] [Full Text]  
  • Lawrence, L. E., Frosco, M., Ryan, B., Chaniewski, S., Yang, H., Hooper, D. C., Barrett, J. F. (2002). Bactericidal Activities of BMS-284756, a Novel Des-F(6)-Quinolone, against Staphylococcus aureus Strains with Topoisomerase Mutations. Antimicrob. Agents Chemother. 46: 191-195 [Abstract] [Full Text]  
  • Bassetti, M., Dembry, L. M., Farrel, P. A., Callan, D. A., Andriole, V. T. (2002). Antimicrobial Activities of BMS-284756 Compared with Those of Fluoroquinolones and {beta}-Lactams against Gram-Positive Clinical Isolates. Antimicrob. Agents Chemother. 46: 234-238 [Abstract] [Full Text]  
  • Wise, R., Gee, T., Marshall, G., Andrews, J. M. (2002). Single-Dose Pharmacokinetics and Penetration of BMS 284756 into an Inflammatory Exudate. Antimicrob. Agents Chemother. 46: 242-244 [Abstract] [Full Text]  
  • Pankuch, G. A., Nagai, K., Davies, T. A., Jacobs, M. R., Appelbaum, P. C. (2002). Antipneumococcal Activity of BMS 284756 Compared to Those of Six Other Agents. Antimicrob. Agents Chemother. 46: 251-254 [Abstract] [Full Text]  
  • Weller, T. M. A., Andrews, J. M., Jevons, G., Wise, R. (2002). The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J Antimicrob Chemother 49: 177-184 [Abstract] [Full Text]  
  • Wu, P., Lawrence, L. E., Denbleyker, K. L., Barrett, J. F. (2001). Mechanism of Action of the Des-F(6) Quinolone BMS-284756 Measured by Supercoiling Inhibition and Cleavable Complex Assays. Antimicrob. Agents Chemother. 45: 3660-3662 [Abstract] [Full Text]  
  • Rodriguez-Cerrato, V., Ghaffar, F., Saavedra, J., Michelow, I. C., Hardy, R. D., Iglehart, J., Olsen, K., McCracken, G. H. Jr. (2001). BMS-284756 in Experimental Cephalosporin-Resistant Pneumococcal Meningitis. Antimicrob. Agents Chemother. 45: 3098-3103 [Abstract] [Full Text]  
  • Discotto, L. F., Lawrence, L. E., Denbleyker, K. L., Barrett, J. F. (2001). Staphylococcus aureus Mutants Selected by BMS-284756. Antimicrob. Agents Chemother. 45: 3273-3275 [Abstract] [Full Text]  
  • Fung-Tomc, J., Valera, L., Minassian, B., Bonner, D., Gradelski, E. (2001). Activity of the novel des-fluoro(6) quinolone BMS-284756 against methicillin-susceptible and -resistant staphylococci. J Antimicrob Chemother 48: 735-738 [Full Text]  
  • Schmitz, F.-J., Boos, M., Jagusch, H., Mayer, S., Fluit, A. C., Hafner, D. (2001). Induction of in vitro resistance to BMS-284756 by Streptococcus pneumoniae. J Antimicrob Chemother 48: 588-590 [Full Text]  
  • Hartman-Neumann, S., DenBleyker, K., Pelosi, L. A., Lawrence, L. E., Barrett, J. F., Dougherty, T. J. (2001). Selection and Genetic Characterization of Streptococcus pneumoniae Mutants Resistant to the Des-F(6) Quinolone BMS-284756. Antimicrob. Agents Chemother. 45: 2865-2870 [Abstract] [Full Text]  
  • Boswell, F. J., Andrews, J. M., Wise, R. (2001). Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 48: 446-447 [Full Text]  
  • Lawrence, L. E., Wu, P., Fan, L., Gouveia, K. E., Card, A., Casperson, M., Denbleyker, K., Barrett, J. F. (2001). The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues. J Antimicrob Chemother 48: 195-201 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»